Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial
NCT04704297
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Rationale: Low back pain (LBP), or myofascial pain syndrome (MPS) of the low back, accounts for approximately 2.63 million visits in the United States, or 2.3 percent of annual Emergency Department (ED) visits. An estimated 100 billion dollars per year is lost from LBP. Approximately one-third of this is direct costs. Previous studies have established the safety of trigger point injections (TPI). However, the results of these studies are highly heterogeneous regarding TPI's ability to treat pain or improve functional outcomes.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Low Back Pain
- Myofascial Pain Syndrome Lower Back
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Madigan Army Medical Center
- Last updated on ClinicalTrials.gov
- January 12, 2021
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- Department of Emergency Medicine, Madigan Army Medical Center · Tacoma, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.